Company news

MeiraGTx Holdings plc news in 2022

MeiraGTx Holdings plc's news releases, calls and decks from 2022, newest first.

View company

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

December 7, 2022

MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.

November 9, 2022

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

October 3, 2022

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

September 30, 2022

MeiraGTx’s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

September 15, 2022

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

August 10, 2022

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

August 2, 2022

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared...

June 27, 2022

MeiraGTx Reports First Quarter 2022 Financial and Operational Results

May 11, 2022

MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

May 3, 2022

MeiraGTx Appoints Debra Yu, MD to Board of Directors

April 26, 2022

MeiraGTx to Participate in Upcoming Investor and Scientific Conferences

April 18, 2022

MeiraGTx Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

March 9, 2022

MeiraGTx Receives Clinical Development Milestone Payment from Janssen

January 26, 2022

Decks in 2022